NCT04313140

Brief Summary

Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help to define the most adapted treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for not_applicable

Timeline
1mo left

Started Feb 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Feb 2021Jun 2026

First Submitted

Initial submission to the registry

March 16, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 18, 2020

Completed
11 months until next milestone

Study Start

First participant enrolled

February 22, 2021

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Last Updated

February 9, 2023

Status Verified

February 1, 2023

Enrollment Period

5.3 years

First QC Date

March 16, 2020

Last Update Submit

February 7, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Validation of the virtual biopsy in the context of gliomas through the use of statistical learning algorithms (artificial intelligence) compared to the biopsy.

    Evaluate the diagnostic capabilities of artificial intelligence algorithms for virtual biopsy based on sensitivity and specificity

    The MRI examination (for 2 hours 30 minutes)

Study Arms (1)

Patient's Glioma grade

EXPERIMENTAL

magnetic resonance spectroscopy

Diagnostic Test: Diagnostic test

Interventions

Diagnostic testDIAGNOSTIC_TEST

The intervention occurs only one time (for 2h30), the MRI examination is divided as follow: * Cinicial MRI (50 minutes) * Research MRI (Phosphorus Spectroscopy, Sodium Imaging)

Patient's Glioma grade

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age≥ 18 years,
  • Patient with suspected glioma with prior imaging
  • Subject free, with legal protection guardianship or curatorship;
  • Enrollment in the French Social Security system;
  • Informed consent signed by the patient

You may not qualify if:

  • Any contraindication to an MRI examination
  • Legal protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons residing in a health or social establishment, adults under legal protection and finally patients in emergency situations
  • Pregnant or lactating women, women of childbearing age who do not have effective contraception

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU De Poitiers

Poitiers, France

RECRUITING

MeSH Terms

Interventions

Diagnostic Tests, Routine

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosis

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 16, 2020

First Posted

March 18, 2020

Study Start

February 22, 2021

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

February 9, 2023

Record last verified: 2023-02

Locations